Last reviewed · How we verify
NCT04453033: LIGHT-PD
DB RCT for Specialized Phototherapy in Parkinson's Disease.
NA trial testing Celeste Specialized Phototherapy Device in Parkinson Disease in 350 participants. Participants enrolled and being followed up; not accepting new ones.
30 June 2026
Quick facts
| Lead sponsor | PhotoPharmics, Inc. |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 350 |
| Start date | 26 February 2024 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 August 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Celeste Specialized Phototherapy Device
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
PhotoPharmics, Inc.
Who can join
45 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pivotal study to determine whether light therapy can improve non-motor and motor function in Parkinson's disease, on top of current best medical treatment.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions.
Sun C, Armstrong MJ. · · 2021 · cited 50× · PMID 33920698 · DOI 10.3390/bs11040054 -
A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson's disease.
Wyman BT, Adams D, Hendrix S, Groves J, et al · · 2025 · cited 2× · PMID 40903343 · DOI 10.1016/j.neurot.2025.e00728 -
Should old acquaintance be forgot: A call for recognition and inclusion of advanced Parkinson's disease patients & care partners in evolving research models.
Park JS, Pensyl C, Manak TJ, Fleisher JE. · · 2025 · PMID 40645862 · DOI 10.1016/j.parkreldis.2025.107949
Verify or expand the search:
- PubMed search for NCT04453033
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other PhotoPharmics, Inc. trials
Trials by the same sponsor.
- NCT05056753 — Heterodyned Whole-Body Vibration in Treatment of Opioid Withdrawal-Induced Anxiety · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04453033 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PhotoPharmics, Inc.
- Last refreshed: 13 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04453033.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing